Fig. 1From: Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studySubject disposition (ITT population). aSubject discontinued CT-P17 treatment due to significant dose delay due to adverse event. bTwo subjects discontinued EU-adalimumab treatment due to subject decision due to adverse event. EU-adalimumab, European Union-approved adalimumab; ITT, intention-to-treatBack to article page